Neuroinflammation Treatment Through Valeric Acid–IL-17 Pathway Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for treating neuroinflammation, particularly postoperative cognitive dysfunction (POCD) and stroke-related neuroinflammation, and the relationship between gut microbiota and neuroinflammation is not well understood, leading to poor neurological outcomes in elderly patients.
Innovation Solution
Modulating the valeric acid-IL-17 pathway through therapies such as exercise, fecal transplantation, and agents targeting IL-17 and FFAR2 to reduce valeric acid and IL-17 levels, thereby stabilizing gut microbiota and reducing neuroinflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gut microbiota is modulated to reduce neuroinflammation, then neurological outcomes improve, but the mechanism and effectiveness are not fully understood
Solution Approach 1:
The patent identifies valeric acid as an intermediary substance produced by gut microbiota that mediates the communication between the gut and brain. Valeric acid acts as a signaling molecule that triggers IL-17 production in the brain, creating a specific molecular pathway (gut microbiota→valeric acid→IL-17→neuroinflammation) that can be targeted for treatment while providing mechanistic insight.
Solution Approach 2:
The patent focuses on changing the concentration parameter of valeric acid in the bloodstream and brain. By modulating gut microbiota composition to reduce valeric acid production, the patent creates a measurable parameter change that correlates with reduced neuroinflammation and improved neurological outcomes, establishing a clear cause-effect relationship.
2Object-affected harmful factors
If valeric acid-IL-17 pathway is targeted for treatment, then neuroinflammation reduces, but treatment complexity increases
Solution Approach 1:
The patent extracts the specific harmful pathway (valeric acid-IL-17 axis) from the complex interplay of gut-brain interactions. By isolating this specific molecular pathway as the primary driver of neuroinflammation, the treatment can be simplified to target only this pathway rather than addressing all possible mechanisms, reducing therapeutic complexity.
Solution Approach 2:
The treatment strategy relies on changing the concentration parameter of valeric acid through gut microbiota modulation. This single parameter change (reducing valeric acid levels) can be achieved through dietary interventions or probiotics, avoiding the need for complex multi-target therapies while effectively reducing neuroinflammation.
3Reliability
If elderly patients receive standard stroke treatment, then immediate symptoms are addressed, but long-term neurological outcome remains poor
Solution Approach 1:
The patent applies preliminary action by modulating gut microbiota and reducing valeric acid production before stroke occurs or in the early recovery phase. This preventive and early intervention approach addresses the root cause of neuroinflammation before it can establish chronic damage, improving long-term outcomes rather than merely managing symptoms.
Solution Approach 2:
The treatment strategy emphasizes continuous modulation of gut microbiota and sustained reduction of valeric acid levels throughout the recovery process. This continuous action maintains the beneficial effect on neuroinflammation over time, providing lasting neurological improvement rather than temporary symptom relief.
Data Source
AI summary
A method of treating neuroinflammation in a subject, the method including administering to a subject a therapy for modulating a valeric acid-interleukin (IL)-17 pathway in the subject so that neuroinflammation in the subject is treated. The therapy administered to the subject can include exercise, fecal transplantation, an agent to decrease bacteria producing valeric acid, an agent for reducing IL-17, and/or an agent for reducing FFAR2, C3ar1, C3, Iba-1, IL-1β, and/or IL-6. Such agents can include RNA interference constructs and/or antibodies. Also provided are methods for improving neurological outcome and/or mediating inflammatory response in a subject suffering from ischemic stroke and/or surgery-induced neuroinflammation.